Reduction in GA lesion growth continues at 18 months with pegcetacoplan

Pegcetacoplan intravitreal injections continued to reduce geographic atrophy lesion growth in patients with age-related macular degeneration at 18 months, according to two phase 3 studies.
The positive long-term results of the DERBY and OAKS studies show that the intravitreal drug has the potential to slow disease progression and preserve a patient’s vision for longer, Apellis Pharmaceuticals announced in a press release.
“Geographic atrophy is a tremendously devastating disease that severely impacts vision and leads to, essentially, loss of vision, legal blindness and loss of

Pegcetacoplan intravitreal injections continued to reduce geographic atrophy lesion growth in patients with age-related macular degeneration at 18 months, according to two phase 3 studies.
The positive long-term results of the DERBY and OAKS studies show that the intravitreal drug has the potential to slow disease progression and preserve a patient’s vision for longer, Apellis Pharmaceuticals announced in a press release.
“Geographic atrophy is a tremendously devastating disease that severely impacts vision and leads to, essentially, loss of vision, legal blindness and loss of